PMID- 33342156
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 42
IP  - 12
DP  - 2020 Dec 23
TI  - [Mechanism of lncRNA-SRLR induced invasion and metastasis in U2OS osteosarcoma 
      cells].
PG  - 1007-1013
LID - 10.3760/cma.j.cn112152-20190404-00216 [doi]
AB  - Objective: To explore the potential mechanism of sorafenib resistance associated 
      long non-coding RNA (lncRNA-SRLR) promoted invasion and metastasis in U2OS 
      osteosarcoma cells. Methods: We transfected U2OS cells with negative control 
      lentivirus (LV-NC) or lncRNA-SRLR overexpressed lentivirus (LV-over/SRLR) 
      particles. LV-NC and LV-over/SRLR stable transfected cells (U20S/NC and 
      U20S/SRLR) were selected by primary cell culture medium containing puromycin. The 
      mRNA expressions of lncRNA-SRLR and procollagen-lysine, procollagen-lysine 
      2-oxoglutarate 5-dioxygenase 2 (PLOD2) were detected by quantitative real-time 
      polymerase chain reaction (qRT-PCR). The effect of lncRNA-SRLR on the invasion of 
      U2OS cells were determined by wound-healing assay and Transwell migration assay. 
      The effect of SRLR on the interleukin-6 (IL-6) secretion of U2OS cells was 
      evaluated by enzyme-linked immunosorbent assay (ELISA) analysis. The subcellular 
      distribution of SRLR in U2OS cells was detected by fluorescence in situ 
      hybridization (FISH) analysis.The expression of PLOD2 in cells was detected by 
      immunofluorescence (IF). The expressions of PLOD2 and focal adhesion kinase 
      (FAK)/signal transducer and activator of transcription 3 (STAT3) signal pathway 
      related proteins in U2OS/NC and U2OS/SRLR cells were detected by western 
      blotting. Results: qRT-PCR assay showed that mRNA expressions of lncRNA-SRLR and 
      PLOD2 in U2OS/SRLR cells were (3 964.97+/-0.05) and (2.77+/-0.11), respectively, 
      significantly higher than those in U2OS/NC cells (P<0.001 or P<0.01). The results 
      of wound-healing and Transwell migration assay showed that over-expression of 
      SRLR markedly promoted the invasion ability of U2OS cells (P<0.05). The result of 
      ELISA analysis showed that the IL-6 secretions in U2OS/NC or U2OS/SRLR cells were 
      (125.38+/-11.22) pg/ml or (119.97+/-13.43) pg/ml, without statistical significance 
      (P>0.05). The subcellular distribution assay revealed that lncRNA-SRLR is 
      predominately located in the nucleus. The result of IF showed that compared with 
      U2OS/NC cells, the expression of PLOD2 was up-regulated in U2OS/SRLR cells. The 
      result of western blotting showed that over-expression of SRLR significantly 
      increased the expression levels of PLOD2, phosphorylation (p)-FAK and p-STAT3 in 
      U2OS cells (P<0.01). Conclusion: lncRNA-SRLR promotes invasion and metastasis of 
      osteosarcoma by activating PLOD2-FAK/STAT3 signal axis.
FAU - Cao, F
AU  - Cao F
AD  - Department of Orthopaedics, Pingdingshan First People's Hospital, Pingdingshan 
      467000, China.
FAU - Kang, X H
AU  - Kang XH
AD  - Department of Oncology, the First Affiliated Hospital of Xinxiang Medical 
      University, Weihui 453100, China.
FAU - Wang, D F
AU  - Wang DF
AD  - Department of Orthopaedics, Pingdingshan First People's Hospital, Pingdingshan 
      467000, China.
FAU - Ma, L
AU  - Ma L
AD  - Department of Orthopaedics, Pingdingshan First People's Hospital, Pingdingshan 
      467000, China.
FAU - Cao, X J
AU  - Cao XJ
AD  - Department of Orthopaedics, Pingdingshan First People's Hospital, Pingdingshan 
      467000, China.
FAU - Wang, Y
AU  - Wang Y
AD  - Department of Oncology, the First Affiliated Hospital of Xinxiang Medical 
      University, Weihui 453100, China.
FAU - Gao, Y Y
AU  - Gao YY
AD  - Department of Oncology, the First Affiliated Hospital of Xinxiang Medical 
      University, Weihui 453100, China.
FAU - Miao, Z H
AU  - Miao ZH
AD  - Department of Oncology, the First Affiliated Hospital of Xinxiang Medical 
      University, Weihui 453100, China.
FAU - Deng, H B
AU  - Deng HB
AD  - Department of Oncology, Longhua Hospital, Shanghai University of Traditional 
      Chinese Medicine, Shanghai 200032, China.
FAU - Gong, Y B
AU  - Gong YB
AD  - Department of Oncology, Yueyang Hospital, Shanghai University of Traditional 
      Chinese Medicine, Shanghai 200437, China.
LA  - chi
GR  - 81503414, 81874392, 82074268/National Natural Science Foundation of China/
GR  - 2017-01-07-00-10-E00064/Project of Scientific Research and Innovation of Shanghai 
      Education Commission/
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (RNA, Long Noncoding)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - *Bone Neoplasms/genetics/metabolism
MH  - Drug Resistance, Neoplasm/genetics
MH  - Humans
MH  - Neoplasm Invasiveness/genetics
MH  - Neoplasm Metastasis/genetics
MH  - *Osteosarcoma/genetics/metabolism
MH  - *RNA, Long Noncoding/metabolism
MH  - Sorafenib/pharmacology
OTO - NOTNLM
OT  - Focal adhesion kinase signal pathway
OT  - Osteosarcoma
OT  - Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2
OT  - Sorafenib resistance associated long non-coding RNA
EDAT- 2020/12/21 06:00
MHDA- 2021/01/20 06:00
CRDT- 2020/12/20 21:56
PHST- 2020/12/20 21:56 [entrez]
PHST- 2020/12/21 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
AID - 10.3760/cma.j.cn112152-20190404-00216 [doi]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2020 Dec 23;42(12):1007-1013. doi: 
      10.3760/cma.j.cn112152-20190404-00216.